Ulcerative keratitis in bullous keratopathy.
OBJECTIVE
The authors review a large series of patients with bullous keratopathy (BK) to analyze the frequency of ulcerative keratitis, and determine the contributory roles of bullae, bandage soft contact lenses, steroids, and prophylactic antibiotics.


METHODS
A retrospective review of all cases of pseudophakic or aphakic bullous keratopathy presenting to the cornea service between January 1, 1986 and September 1, 1995 was performed. The influence of time, bullae, bandage contact lenses, steroids, and prophylactic antibiotics was evaluated by actuarial methods and multivariate analysis.


RESULTS
Nine hundred eighteen patients were included in this study, 44 (4.7%) of whom had infectious or inflammatory complications; 813 cases were available for statistical analysis. Steroids (P < 0.0001), bandage soft contact lens use (P = 0.004), and bullae (P = 0.01) had statistically significant independent effect on the risk of developing ulcerative keratitis, and the combination of steroids and bandage lenses yielded the highest risk (P < 0.001). Propylactic antibiotic use paradoxically had a statistically significant association with ulcerative keratitis in these patients (P = 0.01). Increasing BK time was also associated with ulcer development, and the risk remained relatively constant over the 60 months of the study. Streptococcus was the most frequent organism cultured.


CONCLUSIONS
Ulcerative keratitis developed in 4.7% of patients with bullous keratopathy. Prolonged BK time alone was a risk factor for infection. The strongest single additional risk factor for ulcer development was steroid use, followed by bandage soft contact lens use, and their simultaneous use had the greatest effect. The presence of bullae was also a risk factor for infection, and prophylactic antibiotic use did not prevent ulcer development.
Luchs
J I
JI
Cornea Service, Wills Eye Hospital, Philadelphia, Pennsylvania 19107, USA.
Cohen
E J
EJ
Rapuano
C J
CJ
Laibson
P R
PR
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003315:Cornea / Q000382:microbiology / Q000473:pathology; D003316:Corneal Diseases / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D003320:Corneal Ulcer / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D012189:Retrospective Studies; D012307:Risk Factors; D013290:Streptococcal Infections / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D013291:Streptococcus / Q000302:isolation & purification
D000900:Anti-Bacterial Agents